Oncology Research and Treatment
Original Article · Originalarbeit
Management of Stage I Testicular Seminoma Over a Period of 49 YearsDetti B.a · Scoccianti S.a · Villari D.b · Cipressi S.a · Sardaro A.d · Simontacchi G.a · Livi L.a · Gacci M.e · Cai T.c · Greto D.a · Desideri I.a · Biti G.aa Radiotherapy Unit, Azienda Ospedaliero-Universitaria Careggi, b Clinica Urologica II, University of Florence, c Clinica Urologica, Ospedale di Trento, d Institute of Radiotherapy, University of Bari, e Clinica Urologica I, University of Florence, Italy
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: September 19, 2011
Issue release date: October 2011
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0
ISSN: 2296-5270 (Print)
eISSN: 2296-5262 (Online)
For additional information: https://www.karger.com/ORT
Abstract
Background: The aim of this study was to review the treatment, toxicity, and outcomes in patients with stage I seminoma after orchidectomy. Patients and Methods: A retrospective chart review of all patients with stage I seminoma referred for initial treatment during the last 49 years was performed. Initial treatment approaches, toxicity, and outcomes were analyzed. Results: A total of 320 patients were seen between 1960 and 2009. Median age at diagnosis was 37 years (range: 20–72), with a median follow-up of 22.7 years (range: 1–48). All patients but 12 were treated with adjuvant radiotherapy. Acute toxicity was mainly gastrointestinal, with 7.6% classified as grade 2. The 10-year disease-specific survival and relapse-free survival were 97.7 and 97.6%, respectively. 8 patients (2.7%) developed a relapse and were managed with chemotherapy. 10 patients died, 6 of the disease and 4 from other causes (disease-free at time of death). Conclusion: In the management of stage I seminoma, 3 treatment options are available; currently in the European Consensus, surveillance is the first choice, considering the overall comparable outcome and the low acute and late toxicity. Adjuvant radiotherapy and adjuvant chemotherapy should be considered as alternative options only if the patient declines the surveillance strategy.
© 2011 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Published online: September 19, 2011
Issue release date: October 2011
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0
ISSN: 2296-5270 (Print)
eISSN: 2296-5262 (Online)
For additional information: https://www.karger.com/ORT
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Get Permission